GlassScriptPhysician profile
Shyam Patel
NPI 1124439427
$2,179.53
in general payments reported to CMS, 2019-2025
23 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.84 · 2021: $241 · 2022: $574 · 2023: $793 · 2024: $535 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.92 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.71 | 2021-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.13 | 2021-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $255.47 | 2021-2024 | Stelara, Simponi, Tremfya |
| Celgene Corporation | $101.60 | 2022-2024 | Zeposia |
| Genzyme Corporation | $80.89 | 2023-2024 | |
| Pfizer INC. | $68.12 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $66.58 | 2022-2023 | Linzess |
| Merck Sharp & Dohme LLC | $57.89 | 2021-2023 | Dificid, Zinplava |
| Regeneron Healthcare Solutions, INC. | $53.65 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $48.73 | 2021-2023 | Sucraid |
| Fresenius Kabi USA, LLC | $48.70 | 2023 | Idacio |
| Lilly USA, LLC | $45.00 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $44.78 | 2021 | |
| Ferring Pharmaceuticals INC. | $41.80 | 2022-2023 | Cimzia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $41.08 | 2023-2024 | Ibsrela |
| Erbe USA INC | $32.48 | 2019-2021 | |
| Digestive Care, INC. | $32.36 | 2024 | Pertzye |
| Evoke Pharma, INC. | $29.77 | 2022-2023 | Gimoti |
| Braintree Laboratories, INC. | $26.13 | 2021-2023 | Sutab |
| Gilead Sciences, INC. | $25.89 | 2021-2022 | |
| Redhill Biopharma INC. | $25.44 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.41 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.